Arbutus Biopharma Corp Contracts & Agreements

Executive Employment Agreement, dated effective as of July 10, 2023, between Arbutus Biopharma, Inc. and Karen Sims, MD, PhD (Filed With SEC on August 3, 2023)

Executive Employment Agreement, dated effective as of July 10, 2023, between Arbutus Biopharma, Inc. and J. Christopher Naftzger (Filed With SEC on August 3, 2023)

Option Agreement, dated July 10, 2023, by and between Arbutus Biopharma Corporation and J. Christopher Naftzger (Filed With SEC on August 3, 2023)

Description of Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 (Filed With SEC on March 2, 2023)

Form of Arbutus Biopharma Corporation Restricted Stock (Filed With SEC on March 2, 2023)

Third Amendment to Executive Employment Agreement, dated (Filed With SEC on October 24, 2022)

Arbutus Biopharma Corporation 2016 Omnibus Share and Incentive Plan, as supplemented and amended (Filed With SEC on May 31, 2022)

Description of Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 (Filed With SEC on March 3, 2022)

Form of Arbutus Biopharma Corporation Indemnity Agreement (Filed With SEC on March 3, 2022)

Technology Transfer and Exclusive License Agreement, dated December 13, 2021, by and between the Company and Qilu Pharmaceutical Co., Ltd (Filed With SEC on March 3, 2022)

Third Amendment to Cross License Agreement, dated December 9, 2021, by and between Genevant Sciences GmbH and Arbutus Biopharma Corporation (Filed With SEC on December 10, 2021)

Arbutus Biopharma Corporation 2016 Omnibus Share and Incentive Plan, as supplemented and amended (Filed With SEC on June 1, 2021)

Description of Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 (Filed With SEC on March 4, 2021)

Amendment No. 3 to the Open Market Sale AgreementSM, dated March 4, 2021, by and between Arbutus Biopharma Corporation and Jefferies LLC (Filed With SEC on March 4, 2021)

Cross License Agreement, dated April 11, 2018, by and between the Company and Genevant Sciences Ltd (Filed With SEC on August 7, 2020)

First Amendment to Cross License Agreement, dated June 27, 2018, by and among the Company, Genevant Sciences Ltd. And Genevant Sciences GmbH (Filed With SEC on August 7, 2020)

Second Amendment to Cross License Agreement, dated June 27, 2018, by and among the Company, Genevant Sciences Ltd. And Genevant Sciences GmbH (Filed With SEC on August 7, 2020)

Amendment No. 2 to the Open Market Sale Agreement (Filed With SEC on August 7, 2020)

Arbutus Biopharma Corporation 2016 Omnibus Share and Incentive Plan, as supplemented and amended (Filed With SEC on June 1, 2020)

Arbutus Biopharma Corporation 2020 Employee Stock Purchase Plan (Filed With SEC on June 1, 2020)

Description of Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 (Filed With SEC on March 5, 2020)

Form of Arbutus Biopharma Corporation Indemnity Agreement (Filed With SEC on November 6, 2019)

Offer Letter, dated August 8, 2019, by and between Arbutus Biopharma Corporation and Andrew Cheng (Filed With SEC on November 6, 2019)

Executive Employment Agreement, dated July 10, 2015, by and between Arbutus Biopharma, Inc. and Michael McElhaugh, as amended by the First Amendment to Executive Employment... (Filed With SEC on August 5, 2019)

Purchase and Sale Agreement, dated July 2, 2019, by and between Arbutus Biopharma Corporation and OCM IP Healthcare Portfolio LP (Filed With SEC on August 5, 2019)

Arbutus Biopharma Corporation 2016 Omnibus Share and Incentive Plan, as supplemented (Filed With SEC on August 5, 2019)

Form of Arbutus Biopharma Corporation Option Agreement (Filed With SEC on August 5, 2019)

Option Agreement, dated June 24, by and between Arbutus Biopharma, Inc. and William H. Collier (Filed With SEC on August 5, 2019)

Separation Agreement and Release, dated June 13, 2019, by and between Arbutus Biopharma Corporation and Mark J. Murray (Filed With SEC on June 18, 2019)

Consulting Agreement, dated June 13, 2019, by and between Arbutus Biopharma, Inc. and Mark J. Murray (Filed With SEC on June 18, 2019)

Employment Agreement, dated June 13, 2019, by and between Arbutus Biopharma Corporation and William H. Collier (Filed With SEC on June 18, 2019)

Form of Indemnity Agreement (Filed With SEC on June 18, 2019)

Koert VandenEnden Termination and Severance Agreement (Filed With SEC on May 6, 2019)

Form of Indemnity Agreement (re with initial Agreement by reference to Exhibit 4.15 to the Registrants Annual Report on Form 20-F for the year ended December 31, 2010 filed with... (Filed With SEC on March 7, 2019)

Executive Employment Agreement, dated June 11, 2018, by and between the Company and David Hasting (Filed With SEC on March 7, 2019)

Executive Signing Bonus, dated May 28, 2018, by and between the Company and David Hasting (Filed With SEC on March 7, 2019)

Open Market Sale AgreementSM, dated December 20, 2018, by and between Arbutus Biopharma Corporation and Jefferies LLC (Filed With SEC on December 20, 2018)

Executive Employment Agreement, dated October 8, 2018, by and between Arbutus Biopharma, Inc. and Gaston Picchio (Filed With SEC on November 7, 2018)

Master Contribution And Share Subscription Agreement: Genevant Sciences Ltd. dated April 11, 2018 (Filed With SEC on May 4, 2018)

Termination and Severance Agreement between Arbutus Biopharma Corporation and Bruce Cousins, dated February 8, 2018 (Filed With SEC on March 16, 2018)

Executive Employment Agreement Transfer between Arbutus Biopharma Corporation and Koert VandenEnden., dated February 16, 2018 (Filed With SEC on March 16, 2018)

Indemnity Agreement between Arbutus Biophrama Corporation and Koert VandenEnden, dated February 16, 2018 (Filed With SEC on March 16, 2018)

Roivant Sciences Ltd. Subscription Agreement for Preferred Shares (Filed With SEC on November 2, 2017)

DEPARTMENT OF THE ARMY U.S. ARMY CONTRACTING COMMAND - ABERDEEN PROVING GROUND NATICK CONTRACTING DIVISION 1 KANSAS STREET NATICK, MA ###-###-#### October 1, 2015 (Filed With SEC on March 22, 2017)

DATED 19 October 2016 SETTLEMENT AGREEMENT AND RELEASE between NEUROVIVE PHARMACEUTICAL AB AND ARBUTUS BIOPHARMA CORPORATION (Filed With SEC on March 22, 2017)

LICENSE AGREEMENT by and between ALEXION PHARMA HOLDING on the one hand, and ARBUTUS BIOPHARMA CORPORATION and PROTIVA BIOTHERAPEUTICS INC., on the other hand Dated as of March... (Filed With SEC on March 22, 2017)

LEASE AGREEMENT (Filed With SEC on November 3, 2016)

FIRST AMENDMENT TO LEASE AGREEMENT (Filed With SEC on November 3, 2016)

ACKNOWLEDGMENT OF COMMENCEMENT DATE (Filed With SEC on November 3, 2016)

Award dateGranted #Exercise priceExpiry DateVesting termsOptions vestedAugust 12, 201350,000CAD$16.40 August 11, 20231/4 immed. 1/4 on 1st, 2nd & 3rdanniversary50,000February 5,... (Filed With SEC on November 3, 2016)

NameAward dateGranted #Exercise priceExpiry DateVesting termsMike AbramsDecember 9, 20085,000 $1.80 8-Dec-18ImmediateMike AbramsJanuary 28, 20105,000 $3.85 27-Jan-20ImmediateMike... (Filed With SEC on November 3, 2016)

ARBUTUS BIOPHARMA 2011 OMNIBUS SHARE COMPENSATION PLAN (as approved by the board of directors on May 10, 2011 and approved by the shareholders at the June 22, 2011 Annual and... (Filed With SEC on August 4, 2016)

ARBUTUS BIOPHARMA CORPORATION 2016 OMNIBUS SHARE AND INCENTIVE PLAN (Filed With SEC on August 4, 2016)

Confidential treatment has been requested for portions of this exhibit. The copy filed herewith omits the information subject to the confidentiality request. Omissions are... (Filed With SEC on August 4, 2016)

Exhibit A Form of Release (Filed With SEC on May 4, 2016)

EXECUTIVE EMPLOYMENT AGREEMENT (Filed With SEC on March 9, 2016)

Confidential treatment has been requested for portions of this exhibit. The copy filed herewith omits the information subject to the confidentiality request. Omissions are... (Filed With SEC on March 9, 2016)

FIRST AMENDMENT TO PROTIVA-MONSANTO SERVICES AGREEMENT (Filed With SEC on March 9, 2016)

Letter Agreement between OnCore Biopharma, Inc. and Cytos Biotechnology AG, effective July 16, 2015 (Filed With SEC on November 5, 2015)

License Agreement between OnCore Biopharma, Inc. and Cytos Biotechnology Ltd. dated December 30, 2014 (Filed With SEC on November 5, 2015)

Amending Agreement, dated as of November 2,2015, among Arbutus Biopharma Corporation, Roivant Sciences Ltd., Patrick T. Higgins, Michael J. McElhaugh, Michael J. Sofia and Bryce... (Filed With SEC on November 5, 2015)

Confidential treatment has been requested forportions of this exhibit. The copy filed herewith omits the information subject to the confidentiality request. Omissions are... (Filed With SEC on August 7, 2015)

Confidential treatment has been requestedfor portions of this exhibit. The copy filed herewith omits the information subject to the confidentiality request. Omissions... (Filed With SEC on August 7, 2015)

AMENDMENT OF SOLICITATION/MODIFICATION OF CONTRACT (Filed With SEC on August 7, 2015)

EXECUTIVE EMPLOYMENT AGREEMENT (Filed With SEC on August 7, 2015)

SHARE REPURCHASE AGREEMENT (Filed With SEC on August 7, 2015)

EXECUTIVE EMPLOYMENT AGREEMENT (Filed With SEC on August 7, 2015)

SHARE REPURCHASE AGREEMENT (Filed With SEC on August 7, 2015)

AGREEMENT TO SERVE AS CHIEF DEVELOPMENT OFFICER (Filed With SEC on August 7, 2015)

EXECUTIVEEMPLOYMENT AGREEMENT (Filed With SEC on August 7, 2015)

Confidential treatment has been requested for portions of this exhibit. The copy filed herewith omits the information subject to the confidentiality request. Omissions are... (Filed With SEC on May 6, 2015)

7,500,000 Common Shares TEKMIRA PHARMACEUTICALS CORPORATION (incorporated under the Business Corporations Act (British Columbia)) UNDERWRITING AGREEMENT (Filed With SEC on March 20, 2015)

EMPLOYMENTAGREEMENT (Filed With SEC on March 13, 2015)

EXECUTIVE EMPLOYMENTAGREEMENT (Filed With SEC on March 13, 2015)

Confidential treatment has been requested for portions of this exhibit. The copy filed herewith omits the information subject to the confidentiality request. Omissions are... (Filed With SEC on March 13, 2015)

30-105-04 (Filed With SEC on March 13, 2015)

Confidential treatment has been requested for portions of this exhibit. The copy filed herewith omits the information subject to the confidentiality request. Omissions are... (Filed With SEC on March 13, 2015)

3,750,000 Common Shares TEKMIRA PHARMACEUTICALS CORPORATION (incorporatedundertheBusinessCorporationsAct(BritishColumbia)) UNDERWRITINGAGREEMENT (Filed With SEC on March 13, 2015)

2,125,000 Common Shares TEKMIRA PHARMACEUTICALS CORPORATION (incorporated under the Business Corporations Act (BritishColumbia)) UNDERWRITINGAGREEMENT (Filed With SEC on March 13, 2015)

Confidential treatment has been requestedfor portions of this exhibit. The copy filed herewith omits the information subject to the confidentiality request. Omissions... (Filed With SEC on November 7, 2014)

Confidential treatment has been requested for portions of this exhibit. The copy filed herewith omits the information subject to the confidentiality request. Omissions are... (Filed With SEC on August 14, 2014)

LEASE RENEWAL AND MODIFICATION AGREEMENT (Filed With SEC on August 14, 2014)

EMPLOYMENT AGREEMENT (Filed With SEC on March 28, 2014)

Confidential treatment has been requested for portions of this exhibit. The copy filed herewith omits the information subject to the confidentiality request. Omissions are... (Filed With SEC on March 28, 2014)